Tonghua Dongbao Medicines Company Limited operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Tonghua Dongbao Medicines Company Limited with three other
companies in this sector in China:
China Biologic Products, Inc.
sales of 2.27 billion Chinese Renmimbi [US$329.55 million]
of which 100%
was Human Blood Product),
Beijing Tiantan Biologic.
(2.10 billion Chinese Renmimbi [US$304.22 million]
of which 99%
was Biological products industry), and
Hualan Biological Engineering Inc
(1.93 billion Chinese Renmimbi [US$280.80 million]
of which 94%
was Blood Product).
Tonghua Dongbao Medicines Company Limited reported sales of 2.03 billion Chinese Renmimbi (US$294.70 million)
December of 2016.
increase of 21.7%
versus 2015, when the company's sales were 1.67 billion Chinese Renmimbi.
Sales at Tonghua Dongbao Medicines Company Limited have increased during each of the previous five years
(and since 2011, sales have increased a total of 159%).
Sales of Pharmaceutical saw an increase
19.8% in 2016, from
1.62 billion Chinese Renmimbi to 1.95 billion Chinese Renmimbi.
Not all segments of Tonghua Dongbao Medicines Company Limited experienced an increase in sales in 2016:
sales of Plastic Construction Material fell 43.0% to 26.09 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).